logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

AACR 2018 — TLR9 agonist + pembrolizumab shows early efficacy in PD-1-resistant melanoma

Adding CMP-001 to anti-PD-1 therapy shows promise in this phase 1b trial.